natgillin/translations-raw huggingface dataset:
According to the US National Institute of Neurological Disorders and Stroke (NINDS), a part of the National Institute of Health (NIH), there is currently no way of stopping or reversing the course of Huntington's disease. 
Prema US National Institute of Neurological Disorders and Stroke (NINDS), koji je dio National Institute of Health (NIH), za sada ne postoji način zaustavljanja ili mijenjanja tijeka Huntington-ove bolesti.
H-indazole-3-carboxamide compounds having the following general formula (I) wherein 
Spojevi 1H-indazol-3-karboksamida, koji imaju sljedeću opću formulu (I):
IV) agitating the wet mixture obtained in step III in order to have almost each particle of the gelling agent to be in close/intimate contact with the above mentioned rapidly dissolving diluent 
HR P20120719 TI IV) miješanje vlažne smjese dobivene u koraku kako bi gotovo svaka čestica sredstva za geliranje bila u bliskom/neposrednom kontaktu sa gore navedenim razrjeđivačem za brzo otapanje
In some embodiments the surface relief is embossed with a device for processing a substrate, said device having a tool plan and a reaction plan, the tool plan comprising a multiple layer construction with: 
U nekom ostvarenjima je plošni reljef graviran pomoću uređaja za obradu podloge, pri čemu navedeni uređaj ima ploču za alat i reakcijsku ploču, i pri čemu ploča za alat sadržava višeslojnu konstrukciju s:
Comparative Test-production of a Solution of Roflumilast Based on Water, Poloxamer 188 and Polyethylene Glycol 
Komparativni test - priprema otopine roflumilasta na bazi vode, poloksamera 188 i polietilen glikola
Also included is a pharmaceutical composition comprising a pharmaceutically acceptable excipient, diluent, or carrier and an effective amount of one or more such components of the invention. 
(D) vektor prema zahtjevu 10. Farmaceutski pripravak naznačen time da sadrži farmaceutski prihvatljivu pomoćnu tvar ili farmaceutski prihvatljiv nosač i jedno ili više od slijedećeg:
An oral formulation in tablet form according to claim 1, wherein the tablet further comprises a disintegrant. 
Oralna formulacija u obliku tablete u skladu s patentnim zahtjevom 1, naznačena time što tableta dodatno sadrži sredstvo za raspadanje.
Method as in claim 7, wherein said metal wire passes first through said straightening only unit and then through said drawing unit. 
Postupak prema zahtjevu 7, naznačen time da navedena metalna žica (F) prvo prolazi kroz navedenu jedinicu samo za izravnavanje (11) i zatim kroz navedenu jedinicu za izvlačenje (12).
The compound of claim 22 that is: 
Spoj prema zahtjevu 7 koji je:
The biphasic vesicle composition of claim 1, wherein at least 30% of said interferon alpha-2b and said methionine is entrapped within said vesicles as part of said oil-in-water emulsion. 
Pripravak za uporabu u skladu s patentnim zahtjevom 1, naznačen time, da se najmanje 30 % interferona alfa-2b i L-mctionina u pripravku nalazi u zarobljenoj ulje-u-vodi emulziji.
subjecting said suspension to a heat treatment at a temperature of 70°C or less; 
(c) podvrgavanja navedene suspenzije toplinskoj obradi na temperaturi od 70 *C ili nižoj;
Soft gelatine capsules are preferably enteric coated as described above. 
Kapsule meke želatine su prvenstveno obložene izvana kao što je opisano gore.
An Anabaena variabilis phenylalanine ammonia-lyase (AvPAL) variant, wherein the cysteine residues at positions 503 and 565 of AvPAL have been substituted with serine residues (SEQ ID. 
AvPAL varijanta, naznačena time, da su cisteinski ostaci na položajima 503 i 565 AvPAL- a supstituirani serinskim ostacima (SEQ ID. NO. 11).
The process of item 8, wherein said high pressure second product stream is recycled to the adsorbent bed of said TSA unit. 
što se navedenu struju drugog plinovitog proizvoda pod visokim tlakom reciklira u navedeni sloj ugljičnog adsorbensa od navedene jedinice TSA.
The compound or salt of claim 1 or 9, wherein R8 is hydrogen, fluorine, or methyl. 
Spoj ili sol u skladu s patentnim zahtjevom 1 ili 9, naznačen time što je R8 vodik, fluor ili metil.
Isolated stem cell according to claim 7, wherein the cell further shows 
Izolirana matična stanica u skladu s patentnim zahtjevom 7, pri čemu stanica nadalje pokazuje
In addition, protein resolution depends on the sample volume applied to the column. 
Uz to, rezolucija proteina ovisi o volumenu uzorka nanesenog na kolonu.
The liquefied gas treatment system according to claim 6, further comprising a cooler configured to cool the BOG, which is liquefied by the heat exchanger and is supplied to the decompressing means, by exchanging heat with the liquid component of the BOG which is decompressed to the gas-liquid mixed state while passing through the decompressing means. 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 5, naznačen time što dodatno uključuje hladilo (25), konfigurirano za hlađenje BOG-a, koji se ukapljuje izmjenjivačem topline (21), te šalje u element za dekomprimiranje (22), izmjenom topline s plinovitom komponentom BOG-a, koji se dekomprimira u plinovito-tekuće miješano stanje prilikom prolaska kroz element za dekomprimiranje.
The process of claim 5, wherein the solution is 33% hydrobromic acid in acetic acid. 
Postupak prema patentnom zahtjevu 4, naznačen time, da je otopina 33%-tna bromovodična kiselina u octenoj kiselini.
The combination of claim 1 wherein the compound is selected from the group consisting of: 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što se bira iz skupine koju čine:
In another aspect, the present invention provides a method to treat type II diabetes in a human comprising administering to the human in need of such treatment a pharmaceutical formulation that comprises dapagliflozin or dapagliflozin (S) propylene glycol hydrate; metformin hydrochloride; hydroxypropyl cellulose; microcrystalline cellulose; disintegrant is sodium starch glycolate or hydroxypropyl cellulose, low substituted; and the lubricant is magnesium stearate. 
Farmaceutska formulacija s trenutnim oslobađanjem u obliku tablete, temeljnog standardnog granulata, ili kapsule koja sadrži: (1) SGLT2 inhibitor odabran od dapagliflozina i dapagliflozin (S) propilen glikol hidrata; (2) metformin hidroklorid; hidroksipropil celulozu kao vezivo; mikrokristalnu celulozu kao punilo; natrijev škrob glikolat ili hidroksipropil celuloze, nisko supstituirane kao sredstvo za raspadanje; i magnezijev stearat kao sredstvo za povećanje skliskosti.
The VAP-1 inhibitor for use according to any of claims 1-4 for use in the treatment of a fibrotic condition selected from the group consisting of liver fibrosis and the inflammatory conditions which predispose to it i.e. 
Inhibitor VAP-1, namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1-4, naznačen time što je namijenjen upotrebi u liječenju fibrotičnog stanja koje se bira iz skupine koju čine fibroza jetre 1 upalna stanja koja je predisponiraju prema tome tj.
Mould system according to any one of claims 1 - 8, wherein the inner face of each rim (6, 7), which is oriented towards the mould area, and the mould plate (1), and/or the outer face of the rim (6, 7) and the mould plate, enclose an obtuse angle. 
Sustav kalupa u skladu s bilo kojim od patentnih zahtjeva 2-10, pri čemu unutarnja strana svakog ruba (6, 7) koja je okrenuta području kalupa, i ploča kalupa (1) i/ili vanjska strana ruba (6, 7) i ploča kalupa, zatvaraju tupi kut.
is selected from the group consisting of hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl, wherein aryl, heteroaryl and the substituents for aryl and heteroaryl are as defined above; 
Ri je odabran iz skupine koju čine: vodik, C;-Cgalkil, Cs-Cgcikloalkil, aril, supstituirani aril, heteroaril i supstituirani heteroaril, gdje su aril, heteroaril 1 supstituenti za aril i heteroaril prethodno definirani;
The identification of those subjects who are in need of treatment of herein-described diseases and conditions is well within the ability and knowledge of one skilled in the art. 
Identifikacija onih subjekata kojima je potrebno liječenje bolesti i stanja opisanih u ovoj specifikaciji dobrano je u okviru djelokruga i znanja stručnjaka.
When the active compound is ET-743, active amounts are illustrated by 250 µg and 1 mg. 
Kada je aktivni spoj ET-743, aktivne količine su ilustrirane sa 250 ug i 1 mg.
The yarn as claimed in claim 1-4, wherein the fibres have a staple length from 30 to 60 mm 
Pređa u skladu s patentnim zahtjevom 1, naznačeno time, da pri čemu je dužina sortiranog vlakna od 30 do 60 mm.
Female Swiss athymic (nu/nu genotype) mice were bred and maintained in Alderley Park in negative pressure Isolators (PFI Systems Ltd.). 
Atimusmi miševi Female Swiss (genotipa nu/nu) uzgojeni su i održavani u Alderley Park-u u Izolatorima sa podtlakom (PFI Systems Ltd).
Use according to any of the preceding claims, wherein the component a) is selected from: Equisetum arvense in form of plant or part of plant, juice, dry extract, alcoholic extract, hydro alcoholic extract or glycolic extract, or Equisetum hiemale in form of plant or part of plant, juice, dry extract, alcoholic extract, hydro alcoholic extract or glycolic extract. 
Upotreba prema bilo kojem od prethodnih zahtjeva, naznačena time, da je sastojak a) odabran između: Equisetum arvense u obliku biljke ili dijela biljke, soka, suhog ekstrakta, alkoholnog ekstrakta, hidro alkoholnog ekstrakta ili glikolnog ekstrakta, ili Equisetum hiemale u obliku biljke ili dijela biljke, soka, suhog ekstrakta, alkoholnog ekstrakta, hidro alkoholnog ekstrakta ili glikolnog ekstrakta.
The antibody according to claim 13, wherein said effective amount is about 0.001-50 mg/kilogram of said cells, tissue, organ or animal. 
protutijelo je pogodno za davanje u učinkovitoj količini od oko 0, 1-100 mg/kilogramu navedene životinje; ili
a (C1-8 alkyl)m8j-amino group which may be substituted by one or more R8H, m8j: 0∼2, R8H: [1] a hydroxy group, or [2] a 4- to 10-membered heterocycloalkyl group, a hydroxyl group, 
[1] hidroksi skupina ili [2] 4- do 10-eročlana heterocikloalkilna skupina, (13) hidroksilna skupina, u) C, s alkoksi skupina, koja može biti supstituirana s jednim ili više R*",
Purified water by Modulab or equivalent; 
- > Pročišćena voda s pomoću Modulaba ili njegovog ekvivalenta;
In a further aspect of the invention, a solid oral extended release pharmaceutical dosage form is provided, wherein the active agent is oxycodone hydrochloride and wherein a dosage form comprising 10 mg of oxycodone hydrochloride when tested in a comparative clinical study is bioequivalent to a reference tablet containing 10 mg of oxycodone hydrochloride in a matrix formulation containing: 
Farmaceutski oblik doziranja s produljenim otpuštanjem u krutom obliku prema zahtjevu 1 ili 2, naznačen time da je aktivni agens oksikodon hidroklorid i pri čemu oblik za doziranje kad je testiran u komparativnoj kliničkoj studiji je bioekvivalentan trgovačkom proizvodu OxyContin"".
A method of producing the antibacterial agent according to claim 1 or 2 characterized in that it comprises complexation reaction of carbohydrates and proteins with metal salts and intercalation of iodine into the complex at ionic strength from 5.10-4 to 15 wherein the introduction of said proteins is carried out as an individual step after intercalation of 5 to 95 % iodine. 
Postupak proizvodnje antibakterijskog sredstva prema bilo kojem od zahtjeva 1 ili 2, naznačen time, da obuhvaća reakciju strukturiranja kompleksa ugljikohidrata i proteina s metalnim solima i umetnutim jodom u takav kompleks, uz ionsku snagu od 5.10" do 15, pri čemu se uvođenje navedenih proteina vrši kao pojedinačna faza nakon prethodnog strukturnog umetanja od 5 do 95% joda.
Compounds according to claim 1, wherein the chelating group R3 is a chelating group in free form, salified or complexed with cations or radioactive elements (radionuclides), preferably complexed with a paramagnetic ion, such as Gd3+, Fe3+, or a fluorescent ion, such as Eu3+ or a radionuclide emitting a, B or Y radiations, such as 111In, 99mTc, 169Yb, 177Lu, 90Y or µ213Bi. 
Spojevi u skladu s patentnim zahtjevom 1, naznačeni time što kelirajuća skupina je R3 kelirajuća skupina u slobodnom obliku, u obliku soli ili u obliku kompleksa s kationima ili radioaktivnim elementima (radionuklidima), po mogućnosti u obliku kompleksa s paramagnetskim ionom, poput Gd3+, Fe3+, ili fluorescentnim ionom, poput Eu3+ ili radionuklidom koji emitira a-, B- ili Y-zračenje, poput 111In, 99mTc, 169Yb, 177Lu, 90Y ili 213Bi.
The oral composition of item 35, wherein the agent comprises a statin, bile acid sequestrant (BAS), cholesterol absorption inhibitor fibrate or other PPAR alpha agonist, dual PPAR agonist, lipase inhibitor, protein tyrosine phosphatase 1B inhibitor, pancreatic peptide YY3-36, recombinant or other cannabinoid receptor antagonist or 5-HT2c agonists, such as lorcaserin. 
(b) agens za podizanje HDL-a ili ograničavanje snižavanja HDL-a, opcionalno statin, sekvestrant žučnih kiselina (BAS), inhibitor apsorpcije kolesterola, fibrat ili drugi agonist PPAR alfa, dvostruki PPAR agonist, inhibitor lipaze, inhibitor protein tirozin fosfataze 1B, pankreasni peptid YY334, rekombinantni ili drugi antagonist kanabinoidnog receptora ili 5-HT2c agonist, kao što je lorkaserin;
The method may also include determining, by the computing device, if the binary image of the portable executable file includes a dynamic link library, a kernel driver, or an executable object. 
Postupak kojeg provodi računalo u skladu s patentnim zahtjevom 1, naznačen time što dodatno uključuje usklađivanje, od strane računalnog uređaja, ispravljene prijenosne izvršne datoteke.
A compound of formula 1: wherein R1 is selected from the group consisting of: 
Spoj formule I: [image], naznačen time što se bira iz skupine koju čine:
This in turn causes their release from the latch fingers of the latch sub. 
Posljedica je njihovo oslobađanje od prstiju zasuna elemenata zasuna.
In a first aspect, the present invention thus relates to a method for producing a low fat spread comprising 1-7% whey protein, said method comprising the following steps: 
HR P20120672 T1 PATENTNI ZAHTJEVI Postupak za proizvodnju namaza s niskim sadržajem masti koji sadrži 1-7% proteina sirutke, taj postupak obuhvaća sljedeće korake:
vegetable or animal oil with a melting point below 20° C.; 
najmanje 1%, težinski, biljnog ili životinjskog ulja s talištem ispod 20 "€; ii.
A brewing-type beverage production device, comprising: at least one water reservoir, 
- < najmanje jedan spremnik za vodu (1, 2),
In embodiments as described above the tablet may be formed by direct compression of the composition and cured by at least subjecting said tablet to a temperature of at least about 60 °C, at least about 62 °C, at least about 68 °C, at least about 70 °C, at least about 72 °C or at least about 75 °C for a time period of at least about I minute, at least about 5 minutes or at least about 15 minutes. 
Oblik doziranja sa produljenim otpuštanjem prema bilo kojem od zahtjeva 1 do 12, naznačen time da je u obliku tablete oblikovane pomoću direktnog prešanja pripravka, te koja je stvrdnuta barem podvrgavanjem navedene tablete temperaturi od najmanje oko 60?%C ili najmanje oko 62*C u vremenskom periodu od najmanje oko 1 minute, poželjno najmanje oko 5 minuta ili najmanje oko 15 minuta.
3-(1,3-Benzodioxol-5-yl)-6-(4-cyclopropylpiperazin-1-yl)pyridazine and pharmaceutically acceptable salts and solvates thereof. 
Spoj, naznačen time, da je to 3-(1,3-benzodioksol-5-il)-6-(4-ciklopropilpiperazin-1-il)piridazin ili njegova farmaceutski prihvatljiva sol ili solvat.
The method according to Claim 1, wherein the organic chemical is at least one member selected from the group consisting of o-chlorophenol, p-chlorophenol, 2,4-dichlorophenol, p-tert-butylphenol, 1-naphthol, 3,5-xylenol, carbendazim, 17B-estradiol and bisphenol A. 
Postupak prema zahtjevu 1, naznačen time, da organska kemikalija je barem jedan član odabran iz skupine koja se sastoji od sljedećih: o-klorofenol, p-klorofenol, 2,4-diklorofenol, p-tert-butilfenol, 1-naftol, 3,5-ksilenol, karbendazim, 17B-estradiol i bisfenol A.
said data-link control (21) is able to dynamically allocates communication channels and bandwidth allocation for downstream and upstream information traffics, to a plurality of disparate SMI systems and environment and record said channels and allocated bandwidth within said network connection (28) and bandwidth resource (27) databases, respectively; 
spomenuti uređaj za provjeru podatkovne veze (21) može dinamičko pridjeljivati komunikacijske kanale i širine frekvencijskih pojaseva za protok podataka prema mreži i od mreže prema mnoštvu različitih SMI sustava i okruženja te bilježiti spomenute kanale i pridijeljene širine frekvencijskih pojaseva u spomenutu bazu podataka o spajanju na mrežu (28) odnosno bazu podataka o raspoloživim širinama frekvencijskih pojaseva (27);
A peptide consisting of the sequence LTFGDVVAV (SEQ ID No. 10). 
Peptid koji se sastoji od sekvence aminokiselina prema SEQ ID br. 1.
In accordance with a first aspect of the present invention, there is provided a delayed release drug formulation for oral administration to deliver a drug to the colon of a subject, said formulation comprising a core and a coating for the core, the core comprising a drug and the coating comprising an outer layer and an inner layer, wherein the outer layer comprises a mixture of a first polymeric material which is susceptible to attack by colonic bacteria and a second polymeric material which has a pH threshold at pH 6 or above, and wherein the inner layer comprises a third polymeric material that is soluble in intestinal fluid or gastrointestinal fluid, said third polymeric material being a polycarboxylic acid polymer that is at least partially neutralised with at least 10% of the carboxylic acid groups in the form of carboxylate anions. 
HR P20180965 T1 PATENTNI ZAHTJEVI Formulacija lijeka s produženim otpuštanjem za oralnu primjenu radi davanja lijeka u debelo crijevo pacijenta, pri čemu spomenuti pripravak sadrži: jezgro i prevlaku za jezgru, to jezgru koja sadrži lijek i ovojnicu koja sadrži vanjski sloj i unutarnji sloj; pri čemu vanjski sloj sadrži smjesu prvog polimernog materijala koji je osjetljiv na napad bakterija debelog crijeva i drugi polimerni materijal koji ima prag pH na pH 6 ili više, i pri čemu unutarnji sloj sadrži treći polimerni materijal koji je neionski polimer koji je topljiv u crijevnoj tekućini, ili gastrointestinalnoj tekućini, i najmanje jedan aditiv odabran iz puferskog sredstva i baze.
ii) the other of R8 or R10 is hydrogen or lower alkyl optionally substituted by substituent group A. 
i ii) preostali od RÅ ili R'" je vodik ili niži alkil prema potrebi supstituiran sa supstituentskom skupinom A.
The compound of claim 1, wherein the compound has formula VII 
Spoj sukladno zahtjevu 1, pri čemu spoj ima formulu VII
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) fenpropimorph. 
Pripravak prema zahijevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluoromelil-1-melil-1Hpirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-iljamid, a kao komponentu (B) biksafen.
comprising: reacting a compound of formula 10 or formula 13 wherein R4 is halogen and R2 is as defined above with a diaryldisulfide or a diheterocycledisulfide in the presence of a suitable base in a suitable polar solvent, and 
13 s diaril-disulfidom ili diheterocikl-disulfidom, u prisutnosti pogodne baze, u pogodnom polarnom otapalu, i izdvajanju spoja formule (I) ili formule (II) kao što je definirano gore, gdje R, je XRa.
The use according to claim 12 for treatment of acute and chronic neuropathic pain. 
Uporaba prema zahtjevu 12, naznačena time da joj je svrha liječenje akutne i kronične neuropatske boli.
Physicochemical properties of the sugar such as the geometry, composition, size, flexibility or rigidity, and the relative hydrophilicity can all affect the chemical characteristics of the rapamycin carbohydrate derivative. 
Fizikalno-kemijska svojstva šećera kao što su geometrija, sastav, veličina, fleksibilnost ili rigidnost, te relativna hidrofobnost, mogu utjecati na kemijska svojstva ugljikohidratnog derivata rapamicina.
A further aspect of the invention relates to a device for use in the examination or surgical treatment of a mammalian body, such as a human. 
Daljnji aspekt ovog izuma se odnosi na uređaj koji se koristi kod pregleda ili kod kirurškog zahvata tijela dojke, kao što je humana dojka.
A method for treating an ErbB-2 positive metastatic breast cancer in a subject; comprising administering to the subject neratinib and capecitabine. 
Kombinacija neratiniba i njegovih farmaceutski prikladnih soli s s kapecitabinom za uporabu u postupku liječenja Erb-2 pozitivnog metastatskog raka dojke.
The method according to claim 1, wherein the stage of the cancer is Stage I, Stage II or Stage III colorectal cancer. 
Metoda u skladu sa patentnim zahtjevom 1, gdje je faza raka kolorektalni rak Faza I, Faza II ili Faza III.
A second variation of the inventive pharmaceutical composition is provided for preparing infusion solutions of antimicrobial preparations soluble in sterile water for injections, or in 2% dextrose solution, or in 5% dextrose solution; this composition is provided in a powder form, and comprises: dextrose and colloidal silica, wherein dextrose and colloidal silica constitute a weight ratio of 20:(1-5) or 50:(1-5), wherein (1-5) is a range of changing the weight from 1 unit to 5 units. 
Praškasta smjesa za pripremu infuzijskih otopina antimikrobnih pripravaka topiva u sterilnoj vodi za injektiranje, 2%-tna i 5%-tna otopina dekstroze, naznačena time, da praškasta smjesa sadrži dekstrozu u praškastom obliku i mehanokemijski aktivirani prah koloidnog silicija i dekstroze, pri čemu omjer težine dekstroze 1 koloidnog silicija iznosi 20:1 do 20:5 ili 50:1 do 50:5, a mehanokemijski aktivirani prah aktivira se intenzivnim mehaničkim utjecajem i abrazivnim djelovanjem te sadrži najmanje 35 % čestica koloidnog silicija veličine < 5 um.
The closure for a vial or a plunger for a hypodermic syringe of claim 1 wherein the elastomer material has an absorption coefficient of 1.4-1.6 mm−1. 
Zatvarač za bočicu ili klip za potkožnu špricu u skladu s patentnim zahtjevom 15, naznačen time, što elastomerni materijal ima koeficijent apsorpcije u području od 1.4 - 1.6 mm.
sealing these joined edges of the bag; 
hermetičko spajanje rubova vrećice;
A compound of formula (I) according to anyone of claims 1 to 4, wherein R1 is a group of formula (IIca) as above defined which is connected to the group Y through the carbon adjacent to X2 
jest skupina formule (IIca) kao što je gore definirano, koja je spojena za skupinu Y preko ugljika koji je u susjedstvu X2 [image] (IIca) te gdje X4 jest ugljikov atom, X5 je dušikov atom, X3 je dušikov atom te X2 je skupina –CH–, te R13jest vodik;
6 a and 6 b shown in sectional views details of a fifth embodiment of a beverage dispensing assembly according to the invention. 
Slike 6a i 6b prikazuju u presjeku pojedinosti pete izvedbe sklopa za točenje pića prema izumu.
or a tautomer, pharmaceutically acceptable salt, solvate or clathrate thereof. 
[image] ili njegov tautomer, farmaceutski prihvatljiva sol, solvat ili klatrat, pri čemu:
The nucleic acid according to claim 1 comprising the nucleotide sequence of (a) any one of SEQ ID NOs: 33-36, (b) both SEQ ID NOs: 33 and 34, or (c) both SEQ ID NOs: 35 and 36. 
nukleinska kiselina može sadržavati nukleotidni slijed: (1) bilo koji od 33-36, (2) i SEQ ID NO: 33 i 34, ili (3) i SEQ ID NO: 35 i 36.
(R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile maleic acid salt, for the preparation of a medicament for the treatment of polycythemia vera. 
Postupak pripreme soli prema bilo kojem od patentnih zahtjeva od 1 do 5 koji podrazumijeva kombiniranje (R)-3- (4-(7H-pirolo[2,3-dlpirimidin-4-il)-1H-pirazol-1-il)-3-ciklopentilpropan-nitrila